ReviewFrontiers in immunology2026
An intricate relationship between fibrosis and autoimmune diseases: a specific focus on unraveling its molecular, immunological, and epigenetic drivers.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbial metabolic memory in inflammatory bowel disease: microbiota-derived metabolites, host-microbe reprogramming, and relapse susceptibility.Frontiers in microbiology · 2026Review
- Fibrotic remodeling in the NOD/ShiLtJ mouse model of Sjögren's disease: insights from single-cell transcriptomics and AI-driven ECM quantification.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrosis is a pathological process of wound healing, characterized by excessive deposition of extracellular matrix (ECM) and chronic activation of fibroblasts, leading to organ scarring and a decline in function. Fibrogenesis is predominantly initiated by tissue injury and sustained inflammation, further driven by the complex interplay of growth factors, cytokines, metabolic alterations, and epigenetic reprogramming. Activated myofibroblasts and immune cells function as primary profibrotic mediators. The central molecular pathways implicated include TGF-β/SMAD signaling, non-canonical cascades such as RAS-ERK and PI3K-AKT-mTOR, and integrin-mediated mechanotransduction. These pathways collectively contribute to matrix disruption by upregulating α-SMA, collagen, lysyl oxidase, and tissue inhibitors of metalloproteinases (TIMPs). Alterations in noncoding RNAs and histone/DNA modifications stabilize genes responsible for pro-fibrotic pathways, whereas metabolic reprogramming sustains myofibblast activity. These mechanisms contribute to fibrosis in several autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, Sjögren's disease, and Crohn's disease. In these conditions, persistent immune activation drives continuous crosstalk between immune cells and stromal fibroblasts, sustaining cytokine signaling and ECM remodeling. Current therapeutic approaches primarily aim to halt disease progression; however, achieving true reversal remains challenging. The significant morbidity and mortality associated with fibrotic diseases underscore the need for clinically validated biomarkers to guide effective combined therapeutic regimens capable of reversing established scarring. In this review, we explored emerging strategies that emphasize the integration of immune modulation, epigenetic reprogramming, and mechanobiological interventions to inhibit myofibroblast proliferation and facilitate matrix degradation and tissue regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.